FIH PHASE 1B/2A DOSE ESCALATION STUDY OF EG110A, A NONREPLICATIVE HSV 1-DERIVED GENE THERAPY, VIA INTRADETRUSOR INJECTIONS TO ADULT PARTICIPANTS WITH NDORELATED INCONTINENCE FOLLOWING SCI

Eg427

Investigators